In the original publication values in the results section are incorrect. Errors were also identified in 
RESULTS

Treatment Initiation Patterns with Ripasudil
In the 3016 eyes (patients) included in the efficacy analysis, the numbers of patients classified as ''Add-on (only)'', ''Add-on (with other glaucoma drug)'', ''Switch from prior treatment'', ''Initial monotherapy'' and ''Initial combination therapy'' were 2224 (73.7%), 27 (0.9%), 385 (12.8%), 326 (10.8%) and 54 (1.8%), respectively. The mean number ± SD of glaucoma medicines concomitantly used by patients was 2.3 ± 1.0.
Efficacy
Changes in IOP were also analysed according to the treatment initiation patterns (Fig. 5) . IOP was significantly reduced in all groups: -2.8 ± 4.2 mmHg in 313 eyes in the ''Initial monotherapy'' group, -6.7 ± 9.4 mmHg in 42 eyes in the ''Initial combination therapy'' group, -1.9 ± 4.2 mmHg in 362 eyes in the ''Switch from prior treatment'' group, -2.5 ± 3.8 in 2100 eyes in the ''Add-on (only)'' group, and -3.8 ± 4.0 mmHg in 22 eyes in the ''Add-on (with other glaucoma drug'' group. 
